NovaBay Pharmaceuticals Inc
NBY1.060USD
-0.040-3.64%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
6.17MMarket Cap
2.66P/E TTM
More Details of NovaBay Pharmaceuticals Inc Company
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
NovaBay Pharmaceuticals Inc Info
Ticker SymbolNBY
Company nameNovaBay Pharmaceuticals Inc
IPO dateOct 26, 2007
CEOMr. David E. Lazar
Number of employees14
Security typeOrdinary Share
Fiscal year-endOct 26
Address2000 Powell St Ste 1150
CityEMERYVILLE
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code94608-1804
Phone15108998800
Websitehttps://novabay.com/
Ticker SymbolNBY
IPO dateOct 26, 2007
CEOMr. David E. Lazar
Company Executives of NovaBay Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
933.00
+914.13%
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
67.00
-88.45%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
-100.00%
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
9.78M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
Shareholding Stats
Updated: Sat, Oct 18
Updated: Sat, Oct 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Poplar Point Capital Management LLC
16.99%
C2C Wealth Management, LLC
1.63%
The Vanguard Group, Inc.
0.99%
Geode Capital Management, L.L.C.
0.56%
Rangeley Capital LLC
0.55%
Other
79.28%
Shareholders
Shareholders
Proportion
Poplar Point Capital Management LLC
16.99%
C2C Wealth Management, LLC
1.63%
The Vanguard Group, Inc.
0.99%
Geode Capital Management, L.L.C.
0.56%
Rangeley Capital LLC
0.55%
Other
79.28%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.04%
Investment Advisor
3.13%
Investment Advisor/Hedge Fund
0.56%
Venture Capital
0.34%
Individual Investor
0.09%
Other
77.83%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
37
1.33M
22.07%
-126.95K
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
2023Q2
47
9.53K
10.53%
-5.30K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Poplar Point Capital Management LLC
1.02M
16.99%
--
--
Sep 03, 2025
C2C Wealth Management, LLC
98.00K
1.63%
+43.00K
+78.18%
Jun 30, 2025
The Vanguard Group, Inc.
270.00
0%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
33.82K
0.56%
-1.17K
-3.35%
Jun 30, 2025
Rangeley Capital LLC
33.21K
0.55%
+33.21K
--
Jun 30, 2025
Two Sigma Investments, LP
24.28K
0.4%
+6.81K
+38.96%
Jun 30, 2025
XTX Markets LLC
20.31K
0.34%
+463.00
+2.33%
Jun 30, 2025
Tower Research Capital LLC
5.45K
0.09%
-6.00
-0.11%
Jun 30, 2025
UBS Financial Services, Inc.
3.38K
0.06%
+2.64K
+351.94%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Date
Type
Ratio
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
